Arshad L Jahangir

Address:

7549 W Highland Rdg Dr, Mequon, WI 53092

Phone:

414-763-3248

VIN:

JTHBJ46G372066198

Make:

LEXUS

Model:

LEXUS

Year:

2007

US Patent:

8409192, Apr 2, 2013

Filed:

Feb 20, 2009

Appl. No.:

12/389991

Inventors:

Samuel J. Asirvatham - Rochester MN, US
Arshad Jahangir - Scottsdale AZ, US
Bernard B. C. Lim - Rochester MN, US
Kalpathi L. Venkatachalam - Jacksonville Beach FL, US

Assignee:

Mayo Foundation for Medical Education and Research - Rochester MN

International Classification:

A61B 18/18

US Classification:

606 41

Abstract:

Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.

US Patent:

20120150171, Jun 14, 2012

Filed:

Feb 13, 2012

Appl. No.:

13/371539

Inventors:

Samuel J. Asirvatham - Rochester MN, US
Arshad Jahangir - Rochester MN, US
Bernard B.C. Lim - Rochester MN, US
Kalpathi L. Venkatachalam - Jacksonville Beach FL, US

International Classification:

A61B 18/00
A61N 1/36

US Classification:

606 41, 607 45

Abstract:

Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/C1fA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.

US Patent:

20160151105, Jun 2, 2016

Filed:

Feb 3, 2016

Appl. No.:

15/014991

Inventors:

- Rochester MN, US
Arshad Jahangir - Rochester MN, US
Bernard B.C. Lim - Rochester MN, US
Kalpathi L. Venkatachalam - Jacksonville Beach FL, US

International Classification:

A61B 18/10
A61B 18/08

Abstract:

Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.

US Patent:

20140324040, Oct 30, 2014

Filed:

Jul 14, 2014

Appl. No.:

14/330671

Inventors:

- Rochester MN, US
Arshad Jahangir - Rochester MN, US
Bernard B.C. Lim - Rochester MN, US
Kalpathi L. Venkatachalam - Jacksonville Beach FL, US

International Classification:

A61B 18/14
A61B 18/12

US Classification:

606 34

Abstract:

Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.